Exelixis, Inc. (EXEL) Soars to 52-Week High, Time to Cash Out?

Company Performance - Exelixis shares have increased by 30.2% since the beginning of the year, outperforming the Zacks Medical sector, which declined by 5.1%, and the Zacks Medical - Biomedical and Genetics industry, which fell by 4.2% [1] - The stock recently reached a 52-week high of $49.62, with a monthly increase of 2.3% [1] Earnings and Revenue Expectations - For the current fiscal year, Exelixis is projected to report earnings of $2.61 per share on revenues of $2.34 billion, reflecting a 30.5% increase in EPS and a 7.94% increase in revenues [3] - For the next fiscal year, earnings are expected to rise to $3.03 per share on revenues of $2.65 billion, indicating year-over-year changes of 16.13% in EPS and 13.22% in revenues [3] Valuation Metrics - Exelixis has a Value Score of B, a Growth Score of A, and a Momentum Score of A, resulting in a combined VGM Score of A [6] - The stock trades at 16.6X current fiscal year EPS estimates, below the peer industry average of 19.4X, and at 22.5X trailing cash flow, compared to the peer group's average of 14.6X [7] - The PEG ratio stands at 0.79, indicating that while the stock is not in the top echelon from a value perspective, it still presents a reasonable valuation [7] Zacks Rank - Exelixis holds a Zacks Rank of 2 (Buy), supported by rising earnings estimates, which suggests potential for further price appreciation [8] Industry Context - The Medical - Biomedical and Genetics industry is performing well, ranking in the top 35% of all industries, providing favorable conditions for both Exelixis and its peer, Fortrea Holdings Inc. [11]